CENPE and neoplasm: In addition to KSP, another kinesin family member CENP-E (or KIF10) has also been carried into clinical translational practices, besides the anti-tumor action exerted by CENP-E inhibitor (GSK923295) in preclinical models [171, 172], the results from an inspiring phase I clinical trial further indicated its potential for treatment of refractory solid tumors [173].